176 related articles for article (PubMed ID: 37120435)
21. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
Bhatt M; Ivan C; Xie X; Siddik ZH
Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
[TBL] [Abstract][Full Text] [Related]
22. Tripterygium glycosides reverse chemotherapy resistance in ovarian cancer by targeting the NRF2/GPX4 signal axis to induce ferroptosis of drug-resistant human epithelial ovarian cancer cells.
Ma B; Zhong Y; Chen R; Zhan X; Huang G; Xiong Y; Tan B
Biochem Biophys Res Commun; 2023 Jul; 665():178-186. PubMed ID: 37163938
[TBL] [Abstract][Full Text] [Related]
23. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
24. Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines.
Gralewska P; Gajek A; Marczak A; Rogalska A
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638899
[TBL] [Abstract][Full Text] [Related]
25. Eriodictyol regulated ferroptosis, mitochondrial dysfunction, and cell viability via Nrf2/HO-1/NQO1 signaling pathway in ovarian cancer cells.
Wang X; Chen J; Tie H; Tian W; Zhao Y; Qin L; Guo S; Li Q; Bao C
J Biochem Mol Toxicol; 2023 Jul; 37(7):e23368. PubMed ID: 37020356
[TBL] [Abstract][Full Text] [Related]
26. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
27. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
28. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
29. The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells.
Kong D; Ma S; Liang B; Yi H; Zhao Y; Xin R; Cui L; Jia L; Liu X; Liu X
Biomed Pharmacother; 2012 Jun; 66(4):271-8. PubMed ID: 22564245
[TBL] [Abstract][Full Text] [Related]
30. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.
Chen L; Cheng X; Tu W; Qi Z; Li H; Liu F; Yang Y; Zhang Z; Wang Z
Cell Oncol (Dordr); 2019 Oct; 42(5):679-690. PubMed ID: 31325096
[TBL] [Abstract][Full Text] [Related]
31. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.
Zhao Y; Zhou K; Xia X; Guo Y; Tao L
Cell Cycle; 2023 Jan; 22(2):200-212. PubMed ID: 35959961
[TBL] [Abstract][Full Text] [Related]
32. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
34. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway.
Hu W; Li M; Chen Y; Gu X
J Ovarian Res; 2021 Sep; 14(1):121. PubMed ID: 34535173
[TBL] [Abstract][Full Text] [Related]
35. p53 Plays a Key Role in the Apoptosis of Human Ovarian Cancer Cells Induced by Adenovirus-Mediated CRM197.
Dai L; Pan Q; Peng Y; Huang S; Liu J; Chen T; Wang X; Chen D; Wang J; Zhu Y; Wang H; Liu Y; Ou Y; Yu X; Cao K
Hum Gene Ther; 2018 Aug; 29(8):916-926. PubMed ID: 29620944
[TBL] [Abstract][Full Text] [Related]
36. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
37. The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell.
Chen X; Chen Y; Lin X; Su S; Hou X; Zhang Q; Tian Y
Curr Pharm Biotechnol; 2018; 19(6):506-513. PubMed ID: 30003858
[TBL] [Abstract][Full Text] [Related]
38. MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis.
Wang CK; Chen TJ; Tan GYT; Chang FP; Sridharan S; Yu CA; Chang YH; Chen YJ; Cheng LT; Hwang-Verslues WW
Cancer Res; 2023 Jan; 83(2):251-263. PubMed ID: 36354374
[TBL] [Abstract][Full Text] [Related]
39. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.
Mezzanzanica D; Balladore E; Turatti F; Luison E; Alberti P; Bagnoli M; Figini M; Mazzoni A; Raspagliesi F; Oggionni M; Pilotti S; Canevari S
Clin Cancer Res; 2004 Aug; 10(15):5202-14. PubMed ID: 15297424
[TBL] [Abstract][Full Text] [Related]
40. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
